文献速递肿瘤 PET/CT核素与放射性配体治疗

[68Ga]Ga-PSMA-11 PET/CT在根治性前列腺切除术后复发前列腺癌中的表现:2533例多中心评估

Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-02-04

本回顾性多中心研究纳入2533例根治性前列腺切除术后生化复发的前列腺癌患者,评估[68Ga]Ga-PSMA-11 PET/CT(注射后1小时显像)的诊断表现。结果显示PET/CT阳性率随PSA升高而增加,从PSA≤0.2 ng/ml时的43%升至PSA>10 ng/ml时的93%,且阳性扫描与PSA水平和更高Gleason评分显著相关(p=0.001),而与年龄、注射示踪剂剂量、PSA倍增时间或PSA速率无关。

要点

  • PSA≤0.2 ng/ml时PET/CT阳性率为43%,PSA>10 ng/ml时达93%。
  • 阳性PET/CT与PSA水平及更高Gleason评分显著相关(p=0.001)。
  • 年龄、注射示踪剂剂量、PSA倍增时间和PSA速率与阳性扫描无关。

核心结论

  • [68Ga]Ga-PSMA-11 PET/CT在迄今最大队列中证实了其在高性能,肿瘤检出与更高PSA和更高Gleason评分明确相关。

研究设计与样本

  • 回顾性多中心分析纳入2533例根治性前列腺切除术后复发前列腺癌患者,来自德国海德堡、慕尼黑工业大学和巴西圣保罗爱因斯坦医院核医学科。
  • 所有患者因术后复发接受[68Ga]Ga-PSMA-11 PET/CT,注射后1小时显像。
  • 排除标准包括:未经治疗的原发肿瘤、既往化疗或Xofigo®、仅接受过外照射放疗或HIFU、转诊行PSMA治疗、以及6个月内接受过ADT(包括第一代和第二代ADT)的患者。
  • 多变量分析评估PSA水平、PSA倍增时间(PSADT)、PSA速率(PSAVel)、Gleason评分(GSC,包括7a和7b的单独分析)、年龄和注射示踪剂剂量的潜在影响。

主要发现

  • PET/CT病理性扫描率在PSA≤0.2 ng/ml时为43%,PSA>0.2至≤0.5 ng/ml时为58%,PSA>0.5至≤1.0 ng/ml时为72%,PSA>10 ng/ml时增至最高93%。
  • 病理性PET/CT与PSA水平(p=0.001)和更高GSC显著相关。
  • 注射示踪剂剂量、年龄、PSADT和PSAVel与病理性扫描概率无关。

临床怎么用

  • 对于根治性前列腺切除术后复发患者,[68Ga]Ga-PSMA-11 PET/CT在注射后1小时显像可提供高肿瘤检出率,且检出率随PSA升高而增加。
  • 临床解读时应结合PSA水平和Gleason评分评估PET/CT阳性可能性,年龄、示踪剂剂量、PSADT和PSAVel不影响阳性概率。

局限性

  • 本回顾性分析未报告无进展生存、总生存等结局数据。
  • 原文未报告各PSA区间对应的具体患者例数。
  • 原文未报告多变量分析的具体风险比或置信区间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the performance of [68Ga]Ga-PSMA-11 PET/CT in the diagnosis of recurrent prostate cancer (PC) after prostatectomy in a large multicentre cohort. METHODS: The centres, which contributed to this study, were the departments of nuclear medicine of Heidelberg (Germany), Technical University of Munich (Germany) and Albert Einstein Hospital of São Paulo (Brazil). A total of 2533 patients who were scanned with [68Ga]Ga-PSMA-11 PET/CT at 1 h p.i. due to recurrent PC after prostatectomy were included in this retrospective analysis. Exclusion criteria were as follows: patients with untreated primary tumour, previous chemotherapy or Xofigo®; those previously treated with exclusively external beam radiation therapy or HIFU; those referred for PSMA-therapy; and those treated with ADT (including first- and second-generation ADT) within the last 6 months. Potential influences of different factors such as PSA level, PSA doubling-time (PSADT), PSA velocity (PSAVel), Gleason Score (GSC, including the separate analysis of 7a and 7b), age and amount of injected tracer were evaluated in a multivariable analysis. RESULTS: The rate of pathologic PET/CT-scans was 43% for PSA ≤ 0.2 ng/ml, 58% for PSA > 0.2 to ≤ 0.5, 72% for PSA > 0.5 to ≤ 1.0 and increased to a maximum of 93% for PSA > 10 ng/ml. A pathological PET/CT was significantly (p = 0.001) associated with PSA level and higher GSC. Amount of injected tracer, age, PSADT and PSAVel were not associated with a higher probability of a pathological scan. CONCLUSION: [68Ga]Ga-PSMA-11 PET/CT at 1 h p.i. confirmed its high performance in the largest patient cohort yet analysed. Tumour detection showed a clear association with higher PSA and higher GSC. No association was found between a pathological [68Ga]Ga-PSMA-11 PET/CT and age, amount of injected tracer, PSADT or PSAVel.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Afshar-Oromieh A, da Cunha ML, Wagner J, et al. Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients. Eur J Nucl Med Mol Imaging. 2021. PMID: 33543325. doi:10.1007/s00259-021-05189-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。